Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

DocRosen Dec. 12 at 3:24 AM

$NSPR show me $2.50

0 · Reply

SimpleWinningSetups Dec. 9 at 9:53 PM

Hedge Alert Live - Protect Your Portfolio Contract: $NSPR $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.80 - $3.00 Exit Price Target: $1.31 Profit Margin: +64% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LoyalShark Dec. 9 at 7:30 PM

$NSPR Looking at the chart....its the right question.

0 · Reply

GiveHerTheDD Dec. 8 at 10:55 PM

$NSPR fyi - management disclosed that they will top out the 2.5-3.0 million projection for Q4 revenue. Source: Piper Sandler health conference presentation last week (link on investor tab of website) Good indication that revenue will continually increase throughout 2026.

2 · Reply

JBinLB Dec. 5 at 7:34 PM

$NSPR this turd hasn’t stopped flushing since the day it became tradeable and ppl really still on here defending it 🤡

1 · Reply

HOBOWITHASHOTGUN Dec. 5 at 3:49 PM

$NSPR

0 · Reply

Shadowsdontlie Dec. 5 at 12:54 PM

$NSPR WTF is Slosman doing?

1 · Reply

Threeways Dec. 4 at 1:57 PM

$NSPR BioCardia appointing starvin Marvin to its Board of Directors is hilarious. Can they just take him full time and let him sink that company faster too 😅

1 · Reply

SimpleWinningSetups Dec. 4 at 7:19 AM

0 · Reply

HOBOWITHASHOTGUN Dec. 3 at 3:11 PM

$NSPR We have a 20 X's better story than $CAPR - yet here we sit.

1 · Reply

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Nov 21, 2025, 9:00 AM EST - 23 days ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 19, 2025, 4:42 PM EST - 24 days ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 1:06 PM EST - 5 weeks ago

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 5 weeks ago

InspireMD Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:30 AM EST - 5 weeks ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 7 weeks ago

InspireMD to Announce Third Quarter 2025 Financial Results

Sep 17, 2025, 8:00 AM EDT - 3 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Aug 27, 2025, 9:00 AM EDT - 3 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 4 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 4 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 4 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 4 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 5 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 5 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 6 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 6 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 6 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 7 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 7 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 8 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 8 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Mar 26, 2025, 9:00 AM EDT - 9 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 9 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 9 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 10 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 10 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 2 years ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 2 years ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Dec 20, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

DocRosen Dec. 12 at 3:24 AM

$NSPR show me $2.50

0 · Reply

SimpleWinningSetups Dec. 9 at 9:53 PM

0 · Reply

LoyalShark Dec. 9 at 7:30 PM

$NSPR Looking at the chart....its the right question.

0 · Reply

GiveHerTheDD Dec. 8 at 10:55 PM

2 · Reply

JBinLB Dec. 5 at 7:34 PM

$NSPR this turd hasn’t stopped flushing since the day it became tradeable and ppl really still on here defending it 🤡

1 · Reply

HOBOWITHASHOTGUN Dec. 5 at 3:49 PM

$NSPR

0 · Reply

Shadowsdontlie Dec. 5 at 12:54 PM

$NSPR WTF is Slosman doing?

1 · Reply

Threeways Dec. 4 at 1:57 PM

$NSPR BioCardia appointing starvin Marvin to its Board of Directors is hilarious. Can they just take him full time and let him sink that company faster too 😅

1 · Reply

SimpleWinningSetups Dec. 4 at 7:19 AM

0 · Reply

HOBOWITHASHOTGUN Dec. 3 at 3:11 PM

$NSPR We have a 20 X's better story than $CAPR - yet here we sit.

1 · Reply

Meterdoc Dec. 2 at 8:49 PM

$NSPR Hi poopie!👋👋

1 · Reply

HOBOWITHASHOTGUN Dec. 2 at 3:26 PM

$NSPR We have a 10 X's better story than $PLRZ and yet here we sit.

1 · Reply

Fruitzz Dec. 2 at 2:38 PM

$NSPR 🚀

1 · Reply

SimpleWinningSetups Dec. 1 at 10:12 PM

0 · Reply

LoyalShark Dec. 1 at 9:17 PM

$NSPR lovely groundhog day.

0 · Reply

LoyalShark Dec. 1 at 1:41 PM

$NSPR Sobering to see a CEO like Slosman. For 6 yrs he has dealt Shareholders disappointment. He lacks wisdom when it comes to the markets ....but to his credit ... he gets paid regardless. He gets shares given to him. He gets a big paycheck. He gets to live ina world the retail shareholder only dreams about. The retail shareholder has been neglected and the stock price shows what that means. Sloman is the reason you see NSPR under $2. Slosman is the reason the stock is down 99% since 2019 . Slosman is the reason. Just ask any analyst that follows the stock (all 2 of them - unreal) and they will tell you ....SLOSMAN is the reason. Burning big cash daily. Sell the fkn company NSPR. GEt some balls BOD. Sell the FKN company so we can all move on from this disaster.

0 · Reply

SimpleWinningSetups Nov. 26 at 2:27 AM

0 · Reply

Market Cap	82.62M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	58,500
Avg Vol	120,026
Day's Range	N/A - N/A
Shares Out	42.37M
Stochastic %K	81%
Beta	0.69
Analysts	Strong Sell
Price Target	$4.50